Table 3 Pancreatic cancer study: MTGDR estimates and rank (in meta analysis of marginal effects).
From: Regularized gene selection in cancer microarray meta-analysis
UniGene | Gene name | P1 | P2 | P3 | P4 | Rank |
|---|---|---|---|---|---|---|
Hs.107 | Fibrinogen-like 1 | -0.078 | -0.074 | -0.096 | -0.062 | 1 |
Hs.12068 | Carnitine acetyltransferase | -0.265 | -0.387 | -0.189 | -0.250 | 7 |
Hs.16269 | B-cell CLL/lymphoma 7B | 0.038 | 0.055 | 0.060 | 0.017 | 273 |
Hs.169900 | PABPC4 | -0.879 | -0.992 | -0.693 | -0.775 | 15 |
Hs.180920 | RPS9 ribosomal protein S9 | -0.144 | -0.244 | -0.223 | -0.189 | 53 |
Hs.241257 | transforming growth factor beta binding protein 1 | 0.096 | 0.128 | 0.124 | 0.062 | 11 |
Hs.287820 | Fibronectin 1 | 1.051 | 1.157 | 1.055 | 0.736 | 6 |
Hs.317432 | BCAT1 | -0.023 | -0.012 | -0.053 | -0.022 | 144 |
Hs.5591 | MKNK1 | -0.082 | -0.170 | -0.149 | -0.149 | 56 |
Hs.62 | PTPN12 | 0.111 | 0.100 | 0.104 | 0.126 | 50 |
Hs.66581 | Protein disulfide isomerase family A, member 2 | -0.024 | -0.028 | -0.034 | -0.013 | 3 |
Hs.75335 | GATM | -0.270 | -0.259 | -0.250 | -0.250 | 2 |
Hs.76307 | neuroblastoma, suppression of tumorigenicity 1 | 0.435 | 0.303 | 0.616 | 0.416 | 4 |
Hs.78225 | NBL1 | 0.011 | 0.010 | 0.018 | 0.010 | 64 |
Hs.83383 | Peroxiredoxin 4 | -0.074 | -0.094 | -0.066 | -0.085 | 5 |